Teva Hits Pause On Business Development, Even As Some Deals Stumble
Executive Summary
Teva CEO Erez Vigodman said the company will step away from business development for the “foreseeable future” while it digests the acquisition of Allergan’s generic drug business.
You may also be interested in...
Teva Undertaking Strategic Review As It Searches For New CEO
Execs were pushed for details during earnings call but offer minimal clarity. Teva is sticking by the guidance issued before its loss in Copaxone patent case, and is upping investment in promoting the brand while the decision is appealed.
Teva CEO Steps Down While An Integration Hangs In The Balance
After a damaging court ruling on Copaxone 40 mg and some management missteps, CEO Erez Vigodman will step down as CEO of the Israeli generic drug leader. Chairman Yitzhak Peterburg will fill in on an interim basis.
Teva CEO Steps Down While An Integration Hangs In The Balance
After a damaging court ruling on Copaxone 40 mg and some management missteps, CEO Erez Vigodman will step down as CEO of the Israeli generic drug leader. Chairman Yitzhak Peterburg will fill in on an interim basis.